| Stats | Twitter歴 3,897日（2009/04/14より） |
ツイート数 69,785（17.9件/日） |
表示するツイート :
Naoto T Ueno, MD, PhD@teamoncology
My week on Twitter 🎉: 6 Mentions, 6.88K Mention Reach, 90 Likes, 22 Retweets, 55.2K Retweet Reach. See yours with https://sumall.com/performancetweet?utm_source=twitter&utm_medium=publishing&utm_campaign=performance_tweet&utm_content=text_and_media&utm_term=f68614ae1b9f4c54edcfbdb9… https://pic.twitter.com/ksArfnRU9g
posted at 11:00:41
Naoto T Ueno, MD, PhD@teamoncology
Next year just before @SABCSSanAntonio, MD Anderson @InflammatoryBCa will host the 7th International Inflammatory Breast Cancer conf. 12/6 & 12/7. We have great speakers including Dr Allison, the Nobel laureate. For info contact ibcp@mdanderson.org. #SABCS19 #BCSM #oncoalert https://pic.twitter.com/n9pTFuwXj0
posted at 06:32:31
Naoto T Ueno, MD, PhD@teamoncology
Maintenance immunotherapy is an innovative approach, SAFIR-02. What the need is not just therapy effectiveness but PRO as a primary objective. #SABCS19 #OncoAlert #bcsm
posted at 01:07:35
Naoto T Ueno, MD, PhD@teamoncology
Gepar-X study studies two different nab-paclitaxel dosings and the impact of denosumab. Different doing did not make any difference. Denosumab does not have any antitumor effect.#SABCS19 #bcsm
posted at 00:41:39
Naoto T Ueno, MD, PhD@teamoncology
Selfie. Friends from Korea, Greece, Taiwan, Tunisia. #SABCS19 https://pic.twitter.com/mvGwBxxUJ5
posted at 00:27:10
Naoto T Ueno, MD, PhD@teamoncology
Our biggest fans this week: BldCancerDoc, PhysRelations, AMJohnston1315. Thank you! via https://sumall.com/thankyou?utm_source=twitter&utm_medium=publishing&utm_campaign=thank_you_tweet&utm_content=text_and_media&utm_term=f68614ae1b9f4c54edcfbdb9… https://pic.twitter.com/ShYF1RQihY
posted at 00:02:45
Naoto T Ueno, MD, PhD@teamoncology
One of the best things about this meeting @SABCSSanAntonio is catching up with your old friends. I just met my friend Dr. Montemurro. ##SABCS19 https://pic.twitter.com/V0zBOOpdnD
posted at 23:30:52
Naoto T Ueno, MD, PhD@teamoncology
@MaverickNY Indeed. I wonder why. In the cosmetic world, people use estrogen based cream to juevniate. No evidence but we see this practice. There may be an estrogen pathway that regulates skin tumorigenicity. :)
posted at 23:22:55
Naoto T Ueno, MD, PhD@teamoncology
Long-term follows up confirms that anastrozole is effective to prevent cancer IBIS-II. 49% reduction in postmenopausal women. Impact to the ER+ cancer than ER- diseases. The fracture, DVT, NO DIFFERENCE. Overall anastrozole is a good choice. #BCSM #OncoAlert #SABCS19
posted at 23:07:10
Naoto T Ueno, MD, PhD@teamoncology
pCR rate by immunotherapy shows an interesting outcome.
Why Pembro have pCR improvement but not Atezo? PD1 and PDL1 inhibitor difference? Did types of chemotherapy make a difference? #BCSM #OncoAlert #SABCS19
posted at 22:55:54
Naoto T Ueno, MD, PhD@teamoncology
NeoTRIPPaPDL1 Michelangelo study shows no benefit of atezolizumab addition to preoperative chemotherapy. The pCR rate was 43.5 vs 40.8%. The study primary endpoint if not pCR, is EFS. Still disappointing outcome. #BCSM #OncoAlert #SABCS19
posted at 22:50:31
Naoto T Ueno, MD, PhD@teamoncology
The benefit of Pembrolizumab is striking stronger in Stage III compared to Stage II. IIIA 67 vs. 42%, IIIb 49 vs. 23. It is a major difference in the pCR rate. #BCSM #OncoAlert #SABCS19
posted at 22:46:10
Naoto T Ueno, MD, PhD@teamoncology
KEYNOTE522: first pre-planned interim analysis for EFS shows 91.3 vs 85.3% at 18 months, HR < 0.4, P=0.000051. But it needs long-term follow up. #SABCS19 #BCSM #OncoAlert
posted at 22:42:44
Naoto T Ueno, MD, PhD@teamoncology
Attending the 2nd @SABCSSanAntonio press briefing. #SABCS19 https://pic.twitter.com/eW7cHPWt3K
posted at 22:32:40
Naoto T Ueno, MD, PhD@teamoncology
Short comments & message for capecitabine studies.
Xeloda Metaanalysis NEGATIVE & POSITIVE for TNBC
CBCSG1 Capecitabine to adj chemo. POSITIVE & OUTDATED control
POTENT S-1 POSITIVE but UNAVAILABLE drug in the USA
#SABCS19 #BCSM #OncoAlert
posted at 22:22:53
Naoto T Ueno, MD, PhD@teamoncology
Me too. Super excited. https://twitter.com/thecancergeek/status/1204866790490329091…
posted at 05:57:19
Naoto T Ueno, MD, PhD@teamoncology
@DrHBurstein Do you think that there is a race factor for these factors ?
posted at 02:45:05
Naoto T Ueno, MD, PhD@teamoncology
@DrHBurstein That is true. Thank you for reminding me.
posted at 02:43:52
Naoto T Ueno, MD, PhD@teamoncology
All positive fluoropyridimine outcome studies CBCSG-10, CREATE-X, POTENT studies are from Japan, Korea, & China. Is this because of different drug metabolism among Far East demographic? Do we need to study the benefit in non-Asian population? #bcsm #SABCS19 #OncoAlert
posted at 02:09:45
Naoto T Ueno, MD, PhD@teamoncology
Oral fluropyridine outcome.
Capecitabine for early breast cancer. Meta analysis is negative. Adding capecitabine to taxane/anthracycline showed a benefit. Adding S-1 as one year adjuvant to ER+ high risk shows benefit. #SABCS19 #bcsm #oncoalert
posted at 02:03:12
Naoto T Ueno, MD, PhD@teamoncology
Basically, our standard of care willnot change by five HER2 trials data. We will need to wait for the tucatinib approval. We will need to wait for the outcome of the phase III data for trastuzumab deruxtecan. #SABCS19 #bcsm #OncoAlert https://pic.twitter.com/UCmeB9sUyr
posted at 01:36:48
Naoto T Ueno, MD, PhD@teamoncology
APT study, to use T-DM1, we need to consider expected toxicities and financial toxicity. #SABCS19
posted at 01:07:15
Naoto T Ueno, MD, PhD@teamoncology
One word HER2 study outcome & catch!
HER2CLIMB Tucanitib POSITIVE & EXCITING.
DESTINY Tarstuzumab deruxtecan PROMING & ILD.
SOPHIA Margetuxumab DISAPPOINTING & biomarker.
AFINITY Pertuzumab/trastuzumab WEAK & SELECTION
ATEMPT APT vs T-DM1 SAME & PRO #SABCS19 #OncoAlert #bcsm
posted at 01:05:27
Naoto T Ueno, MD, PhD@teamoncology
DESTIY01 study. Objective response is 60%. The data shows pretty much most patients had some kind of response. Lots of nausea. #SABCS19 #OncoAlert #bcsm https://twitter.com/nejm/status/1204750178043006977…
posted at 00:26:47
Naoto T Ueno, MD, PhD@teamoncology
SOPHIA study show a disappointing outcome compared to tucatinib. There may be a potential benefit in certain immunological unique population. #SABCS19 #bcsm #OncoAlert https://pic.twitter.com/Vk0GADLOBX
posted at 00:19:33
Naoto T Ueno, MD, PhD@teamoncology
You wonder, do you need capecitabine or trastuzumab for tucanitib containing regimen. #SABCS19 #OncoAlert #bcsm
posted at 00:14:02
Naoto T Ueno, MD, PhD@teamoncology
Here is the original paper of HER2Climb study. https://twitter.com/nejm/status/1204776602145439744…
posted at 00:01:40
Naoto T Ueno, MD, PhD@teamoncology
Finally, we have a drug tucanitib, when combined with trastuzumab and Xeloda that will help HER2 brain met. New standard of care after T-DM1 and trastuzumab-pertuzumab containing regimen. #SABCS19 #bcsm
posted at 00:00:33
Naoto T Ueno, MD, PhD@teamoncology
HER2CLIMB presented by Dr @rashmikmurthy @MDAndersonNews shows tucatinib combined with trastuzumab/capecitabine shows improvement in both PFS & OS compared to t&c. ALSO BENEFIT IN BRAIN MET. More diarrhea. #SABCS19 #BCSM #endcancer https://pic.twitter.com/jHdG9ZE9Zv
posted at 23:54:23
Naoto T Ueno, MD, PhD@teamoncology
Ellen Pure from @PennCancer states finding a cancer specific target is not easy. Better way approach may be targeting the stroma surrounding cancer, there is more genetically stable target for drug devlopment, such as FAP. #SABCS19 #OncoAlert #bcsm https://pic.twitter.com/b0DzcmAxHW
posted at 23:40:46
Naoto T Ueno, MD, PhD@teamoncology
Why we die? #SABCS19 #bcsm http://img0.joyreactor.cc/pics/post/%D1%81%D0%BC%D0%B5%D1%80%D1%82%D0%BD%D0%BE%D1%81%D1%82%D1%8C-%D1%81%D1%82%D0%B0%D1%82%D0%B8%D1%81%D1%82%D0%B8%D0%BA%D0%B0-%D0%B3%D0%B8%D1%84%D0%BA%D0%B8-5580928.gif?fbclid=IwAR3xk-dC7h_OsabZGzIapdBzEAzcgC4mCbXJxJprcmlGif74B1tbY9TOJvE…
posted at 20:06:26
Naoto T Ueno, MD, PhD@teamoncology
Our randomized clinical trial clearly has shown that the CYP2D6 Genotype–Guided Tamoxifen Dosing does not help the patients. #bcsm #sabcs19 @oncoalert https://ascopubs.org/doi/full/10.1200/JCO.19.01412#.XfBD56K-z-c.twitter…
posted at 10:19:03
Naoto T Ueno, MD, PhD@teamoncology
My first #SABCS19 selfie @iah. @united flight packed with breast cancer experts and my friends. https://pic.twitter.com/pHTf64Dj3B
posted at 00:08:31
Naoto T Ueno, MD, PhD@teamoncology
#SABCS19 starting today. Gloomy day in Houston. Hope to see a better weather at San Antonio. The world’s largest breast cancer meeting. Follow #SABCS19. I will focus on the take home messages and inflammatory breast cancer related stuff. Love to take selfie, reach out to me.
posted at 22:49:39
Naoto T Ueno, MD, PhD@teamoncology
Temp up and down. A typical TEXAS weather. #SABCS19
posted at 22:30:06
Naoto T Ueno, MD, PhD@teamoncology
An impressive list of presentations/moderators/speakers from @MDAndersonNews at #SABCS19 starting from tomorrow. The link provides the list of MD Anderson's engagement, prepared by @thecancergeek.
Chance to meet our MDA colleagues. #endcancer
https://docs.google.com/document/d/1kxgZdIcUumU_SmjewEeOphclPJNatcFyQizqgfUtRL0/edit?ts=5ded8a53…
posted at 06:48:26
Naoto T Ueno, MD, PhD@teamoncology
At #SABCS19, @InflammatoryBCa will host a "Meet the Experts Session scheduled for IBC Thursday," December 12th @ 3PM @ the MD Anderson (@MDAndersonNews) Booth #226. Meet my colleagues and me. #endcancer #bcsm #talkibc
posted at 06:04:17
Naoto T Ueno, MD, PhD@teamoncology
@curijoey Yes!!
posted at 02:46:30
Naoto T Ueno, MD, PhD@teamoncology
Fantastic. Transplant docs are the pioneers of the ultimate form of immunotherapy with a curative form even before the immune checkpoint inhibitors. Very proud of their work!! #endcancer https://twitter.com/bldcancerdoc/status/1203325815532015616…
posted at 21:03:40
Naoto T Ueno, MD, PhD@teamoncology
日本の鉄道切符てほとんど英語がないんだよね。他の言葉で発券する努力をJRと私鉄はして欲しい。JAPAN needs to make an effort to issue a railroad ticket in other languages. It is pretty much clueless tickets for now.
posted at 20:59:24
Naoto T Ueno, MD, PhD@teamoncology
@curijoey Well said!!
posted at 12:09:00
Naoto T Ueno, MD, PhD@teamoncology
.@MedicalCollege Wisconsin opens an inflammatory breast cancer clinic. @CooperHospital @ScrippsHealth and Medical College of Wisconsin working together with @InflammatoryBCa Our goal is to provide same quality of care regardless of the location. #talkibc #endcancer
posted at 02:52:19
Naoto T Ueno, MD, PhD@teamoncology
@SABCSSanAntonio Update of KEYNOTE522 update, adj atezo, adjuvant capecitabine data, KX-ORAX-001, role of neoadjuvant cisplatin for BRCA mutation, lots of interesting stuff. #SABCS19
posted at 02:46:49
Naoto T Ueno, MD, PhD@teamoncology
Exciting @SABCSSanAntonio starting from Next Tuesday. Lots of anti-HER2 trial update. APHINITY, pertuzumab OS, HER2Climb tucatininb, DESTINYbreast01 - DS8201 HER2-ADC, ATEMPT (adjuvant TDM1), ATEMPT - adjuvant TDM1 #SABCS19
posted at 02:36:20
Naoto T Ueno, MD, PhD@teamoncology
My week on Twitter 🎉: 1 Mention, 36 Likes, 1 Retweet, 471 Retweet Reach. See yours with https://sumall.com/performancetweet?utm_source=twitter&utm_medium=publishing&utm_campaign=performance_tweet&utm_content=text_and_media&utm_term=f68614ae1b9f4c54edcfbdb9… https://pic.twitter.com/OhxTVAmoD0
posted at 11:00:36
Naoto T Ueno, MD, PhD@teamoncology
Our biggest fans this week: Morgan_Simba. Thank you! via https://sumall.com/thankyou?utm_source=twitter&utm_medium=publishing&utm_campaign=thank_you_tweet&utm_content=text_and_media&utm_term=f68614ae1b9f4c54edcfbdb9… https://pic.twitter.com/wTIiKyxzlY
posted at 00:03:24
Naoto T Ueno, MD, PhD@teamoncology
Holiday season started at MD Anderson Cancer Center. https://pic.twitter.com/aBAvn2oO5R
posted at 00:51:20
Naoto T Ueno, MD, PhD@teamoncology
The rate of opioid abuse or dependence was 2.9% among the cancer survivors. They identified factors that will predict the abuse. If you do not have depression, H/O opioid use, the dependency is on the low side. Of course, we still need to be careful.
https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djz200/5618684…
posted at 22:42:48
Naoto T Ueno, MD, PhD@teamoncology
My week on Twitter 🎉: 14 Mentions, 10.1K Mention Reach, 25 Likes, 11 Retweets, 5.36K Retweet Reach. See yours with https://sumall.com/performancetweet?utm_source=twitter&utm_medium=publishing&utm_campaign=performance_tweet&utm_content=text_and_media&utm_term=f68614ae1b9f4c54edcfbdb9… https://pic.twitter.com/5JWOJdN1Ks
posted at 11:00:19
Naoto T Ueno, MD, PhD@teamoncology
Our biggest fans this week: kj_hashi, COOTIE_0215, JPerfumeMed. Thank you! via https://sumall.com/thankyou?utm_source=twitter&utm_medium=publishing&utm_campaign=thank_you_tweet&utm_content=text_and_media&utm_term=f68614ae1b9f4c54edcfbdb9… https://pic.twitter.com/ijr7lNw8vt
posted at 00:03:01
